Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 26 | 2015 | 2862 | 1.470 |
Why?
|
Neoplasms | 21 | 2023 | 2881 | 1.340 |
Why?
|
Neoplasm Metastasis | 19 | 2016 | 1056 | 1.140 |
Why?
|
Prostatic Neoplasms | 9 | 2007 | 1703 | 0.720 |
Why?
|
Radiotherapy | 6 | 2014 | 326 | 0.720 |
Why?
|
Epigenesis, Genetic | 1 | 2023 | 468 | 0.700 |
Why?
|
Antineoplastic Agents | 8 | 2015 | 2350 | 0.520 |
Why?
|
Knowledge | 1 | 2014 | 29 | 0.500 |
Why?
|
Education, Medical | 2 | 2014 | 231 | 0.480 |
Why?
|
Neovascularization, Pathologic | 6 | 2004 | 352 | 0.480 |
Why?
|
Models, Theoretical | 3 | 2005 | 479 | 0.460 |
Why?
|
Physicians, Primary Care | 1 | 2014 | 104 | 0.450 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2004 | 845 | 0.430 |
Why?
|
Humans | 72 | 2023 | 86102 | 0.430 |
Why?
|
Lymphatic Metastasis | 8 | 2003 | 480 | 0.420 |
Why?
|
Physician-Patient Relations | 4 | 2007 | 610 | 0.400 |
Why?
|
Radiation, Ionizing | 4 | 2010 | 121 | 0.390 |
Why?
|
Radiation Oncology | 3 | 1997 | 119 | 0.370 |
Why?
|
Human Experimentation | 1 | 2010 | 39 | 0.360 |
Why?
|
Nucleoside-Diphosphate Kinase | 2 | 2000 | 11 | 0.350 |
Why?
|
Ethics, Research | 1 | 2010 | 52 | 0.350 |
Why?
|
Monomeric GTP-Binding Proteins | 2 | 2000 | 18 | 0.350 |
Why?
|
Disease-Free Survival | 12 | 2011 | 1203 | 0.350 |
Why?
|
Patient Advocacy | 3 | 2015 | 49 | 0.340 |
Why?
|
MicroRNAs | 4 | 2015 | 534 | 0.330 |
Why?
|
Chemotherapy, Adjuvant | 8 | 2005 | 459 | 0.320 |
Why?
|
Genetic Therapy | 9 | 2008 | 342 | 0.320 |
Why?
|
Physician's Role | 4 | 2005 | 179 | 0.320 |
Why?
|
Models, Economic | 1 | 2007 | 60 | 0.300 |
Why?
|
Hematopoiesis | 1 | 2008 | 163 | 0.300 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2005 | 1293 | 0.300 |
Why?
|
Neoplastic Stem Cells | 1 | 2008 | 143 | 0.290 |
Why?
|
Liver Neoplasms | 3 | 2018 | 720 | 0.280 |
Why?
|
Prostatectomy | 3 | 2007 | 453 | 0.280 |
Why?
|
Decision Making | 3 | 2007 | 640 | 0.280 |
Why?
|
Tumor Necrosis Factor-alpha | 7 | 2008 | 683 | 0.280 |
Why?
|
Androgen Antagonists | 2 | 2005 | 140 | 0.280 |
Why?
|
Hematopoietic Stem Cells | 1 | 2008 | 291 | 0.280 |
Why?
|
Prognosis | 11 | 2005 | 3660 | 0.270 |
Why?
|
Transcription Factors | 6 | 2004 | 1540 | 0.270 |
Why?
|
Attitude of Health Personnel | 2 | 2005 | 636 | 0.270 |
Why?
|
Colorectal Neoplasms | 3 | 2018 | 924 | 0.260 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2003 | 150 | 0.260 |
Why?
|
Prostate-Specific Antigen | 2 | 1998 | 346 | 0.250 |
Why?
|
Ethics, Medical | 3 | 2000 | 306 | 0.250 |
Why?
|
Attitude to Health | 1 | 2005 | 220 | 0.250 |
Why?
|
Nitriles | 1 | 2004 | 143 | 0.240 |
Why?
|
Triazoles | 1 | 2004 | 95 | 0.230 |
Why?
|
Biomedical Research | 3 | 2014 | 375 | 0.230 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2023 | 69 | 0.230 |
Why?
|
History, 20th Century | 3 | 2010 | 312 | 0.220 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2003 | 63 | 0.220 |
Why?
|
Managed Care Programs | 2 | 2000 | 42 | 0.220 |
Why?
|
Brachytherapy | 1 | 2003 | 119 | 0.210 |
Why?
|
Melanoma | 2 | 2013 | 454 | 0.200 |
Why?
|
Proliferating Cell Nuclear Antigen | 2 | 2000 | 66 | 0.200 |
Why?
|
Disease Progression | 8 | 2012 | 1526 | 0.200 |
Why?
|
Lymph Nodes | 4 | 2000 | 529 | 0.200 |
Why?
|
Lymph Node Excision | 1 | 2003 | 211 | 0.200 |
Why?
|
Aged | 16 | 2018 | 18331 | 0.200 |
Why?
|
Biomarkers, Tumor | 3 | 2003 | 1459 | 0.200 |
Why?
|
Medical Oncology | 2 | 2014 | 357 | 0.190 |
Why?
|
Female | 31 | 2018 | 44359 | 0.190 |
Why?
|
Carcinoma | 1 | 2003 | 433 | 0.190 |
Why?
|
Survival Analysis | 6 | 2013 | 1536 | 0.180 |
Why?
|
Combined Modality Therapy | 9 | 2005 | 1661 | 0.180 |
Why?
|
Skin Neoplasms | 1 | 2004 | 541 | 0.170 |
Why?
|
Clinical Trials as Topic | 4 | 2014 | 1168 | 0.170 |
Why?
|
Cadherins | 1 | 2000 | 151 | 0.170 |
Why?
|
Radiosurgery | 2 | 2013 | 265 | 0.170 |
Why?
|
Middle Aged | 16 | 2018 | 24935 | 0.170 |
Why?
|
Mammography | 2 | 2000 | 460 | 0.170 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2005 | 291 | 0.160 |
Why?
|
Gene Amplification | 1 | 2018 | 131 | 0.160 |
Why?
|
History, 21st Century | 2 | 2009 | 175 | 0.150 |
Why?
|
Immediate-Early Proteins | 4 | 2004 | 164 | 0.140 |
Why?
|
Mastectomy | 2 | 2004 | 234 | 0.140 |
Why?
|
Quality of Health Care | 1 | 2000 | 380 | 0.140 |
Why?
|
Antigens, Neoplasm | 1 | 1998 | 324 | 0.140 |
Why?
|
Disease Models, Animal | 4 | 2016 | 2225 | 0.140 |
Why?
|
Prescription Fees | 1 | 2015 | 10 | 0.140 |
Why?
|
Consumer Advocacy | 1 | 1995 | 10 | 0.130 |
Why?
|
Insurance Coverage | 1 | 1996 | 115 | 0.130 |
Why?
|
Microcirculation | 3 | 2000 | 103 | 0.130 |
Why?
|
United States | 7 | 2015 | 6628 | 0.130 |
Why?
|
Health Care Rationing | 1 | 1996 | 83 | 0.130 |
Why?
|
Aged, 80 and over | 7 | 2018 | 6481 | 0.130 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2015 | 49 | 0.130 |
Why?
|
Drug Costs | 1 | 2015 | 62 | 0.130 |
Why?
|
Erectile Dysfunction | 2 | 2007 | 71 | 0.130 |
Why?
|
Neoplasm Staging | 5 | 2004 | 1932 | 0.130 |
Why?
|
Patients | 1 | 1995 | 100 | 0.120 |
Why?
|
Medical Laboratory Science | 1 | 1994 | 7 | 0.120 |
Why?
|
Radiotherapy, Computer-Assisted | 2 | 2008 | 25 | 0.120 |
Why?
|
Clinical Medicine | 1 | 1994 | 34 | 0.120 |
Why?
|
Aging | 1 | 1998 | 689 | 0.120 |
Why?
|
Life Expectancy | 1 | 1994 | 85 | 0.120 |
Why?
|
Genetic Engineering | 1 | 1994 | 113 | 0.120 |
Why?
|
Urinary Incontinence | 2 | 2007 | 200 | 0.110 |
Why?
|
Patient Participation | 1 | 2015 | 216 | 0.110 |
Why?
|
Male | 13 | 2018 | 40834 | 0.110 |
Why?
|
Adult | 12 | 2018 | 25559 | 0.110 |
Why?
|
History, 19th Century | 2 | 2009 | 59 | 0.110 |
Why?
|
Health Care Reform | 1 | 1994 | 90 | 0.110 |
Why?
|
Data Interpretation, Statistical | 2 | 2004 | 297 | 0.100 |
Why?
|
Treatment Outcome | 6 | 2013 | 7933 | 0.100 |
Why?
|
Diagnostic Imaging | 1 | 2015 | 468 | 0.100 |
Why?
|
Evidence-Based Medicine | 2 | 2005 | 429 | 0.100 |
Why?
|
Animals | 15 | 2016 | 26469 | 0.100 |
Why?
|
Informed Consent | 2 | 2010 | 266 | 0.100 |
Why?
|
Neoplasm Transplantation | 6 | 2016 | 391 | 0.100 |
Why?
|
Age Factors | 3 | 2007 | 1842 | 0.100 |
Why?
|
Philosophy, Medical | 2 | 2005 | 17 | 0.090 |
Why?
|
Follow-Up Studies | 4 | 2000 | 3613 | 0.090 |
Why?
|
Multivariate Analysis | 3 | 1998 | 997 | 0.090 |
Why?
|
Ohio | 1 | 2010 | 36 | 0.090 |
Why?
|
Tamoxifen | 2 | 2004 | 167 | 0.090 |
Why?
|
Hodgkin Disease | 1 | 1991 | 177 | 0.090 |
Why?
|
Biological Evolution | 1 | 1997 | 916 | 0.090 |
Why?
|
NM23 Nucleoside Diphosphate Kinases | 2 | 2000 | 5 | 0.090 |
Why?
|
Lung | 2 | 2012 | 1165 | 0.090 |
Why?
|
Research Subjects | 1 | 2010 | 73 | 0.090 |
Why?
|
X-Ray Therapy | 1 | 2008 | 6 | 0.090 |
Why?
|
Universities | 1 | 2010 | 135 | 0.090 |
Why?
|
Cell Line, Tumor | 5 | 2015 | 2419 | 0.080 |
Why?
|
Lung Neoplasms | 3 | 2013 | 2258 | 0.080 |
Why?
|
Analysis of Variance | 2 | 2004 | 912 | 0.080 |
Why?
|
Military Personnel | 1 | 2010 | 84 | 0.080 |
Why?
|
Adenocarcinoma | 3 | 2012 | 1160 | 0.080 |
Why?
|
Survival Rate | 3 | 2012 | 1855 | 0.080 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2008 | 94 | 0.080 |
Why?
|
Melanoma, Experimental | 1 | 2008 | 103 | 0.080 |
Why?
|
Radiotherapy, Conformal | 1 | 2008 | 83 | 0.080 |
Why?
|
Philosophy | 1 | 2007 | 9 | 0.080 |
Why?
|
Urethral Stricture | 1 | 2007 | 11 | 0.080 |
Why?
|
Rectal Diseases | 1 | 2007 | 24 | 0.080 |
Why?
|
Practice Patterns, Physicians' | 1 | 1993 | 578 | 0.080 |
Why?
|
Critical Pathways | 1 | 2007 | 35 | 0.080 |
Why?
|
DNA-Binding Proteins | 4 | 2004 | 1204 | 0.080 |
Why?
|
Mutation | 1 | 2018 | 3948 | 0.070 |
Why?
|
Actuarial Analysis | 2 | 1997 | 66 | 0.070 |
Why?
|
Time Factors | 4 | 2005 | 5198 | 0.070 |
Why?
|
Phenotype | 3 | 2015 | 2369 | 0.070 |
Why?
|
Fund Raising | 1 | 2005 | 2 | 0.070 |
Why?
|
Academies and Institutes | 1 | 2006 | 31 | 0.070 |
Why?
|
Predictive Value of Tests | 3 | 2003 | 1671 | 0.070 |
Why?
|
Gene Expression Regulation | 3 | 2002 | 1903 | 0.070 |
Why?
|
Dermatology | 1 | 2006 | 35 | 0.070 |
Why?
|
Immunohistochemistry | 3 | 2000 | 1752 | 0.070 |
Why?
|
Gene Expression Profiling | 3 | 2018 | 1378 | 0.070 |
Why?
|
Trastuzumab | 1 | 2005 | 67 | 0.070 |
Why?
|
Heterografts | 2 | 2015 | 98 | 0.060 |
Why?
|
Sample Size | 1 | 2005 | 129 | 0.060 |
Why?
|
Mastectomy, Radical | 2 | 1995 | 10 | 0.060 |
Why?
|
Drug Administration Schedule | 2 | 2003 | 916 | 0.060 |
Why?
|
Patient Satisfaction | 1 | 2007 | 449 | 0.060 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2004 | 110 | 0.060 |
Why?
|
Databases, Factual | 1 | 2007 | 807 | 0.060 |
Why?
|
Doxorubicin | 1 | 2004 | 288 | 0.060 |
Why?
|
Radiation Dosage | 2 | 2011 | 226 | 0.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2004 | 2430 | 0.060 |
Why?
|
Carcinoma, Lewis Lung | 2 | 2000 | 23 | 0.060 |
Why?
|
Neoplasm Invasiveness | 1 | 2004 | 542 | 0.050 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2005 | 427 | 0.050 |
Why?
|
Mice | 9 | 2015 | 11279 | 0.050 |
Why?
|
Interdisciplinary Communication | 1 | 2003 | 130 | 0.050 |
Why?
|
Surgical Procedures, Operative | 1 | 2004 | 182 | 0.050 |
Why?
|
Early Growth Response Protein 1 | 4 | 2004 | 54 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 2 | 2018 | 859 | 0.050 |
Why?
|
Lymphedema | 1 | 2003 | 77 | 0.050 |
Why?
|
Transcriptional Activation | 1 | 2002 | 279 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2003 | 1987 | 0.050 |
Why?
|
Coumarins | 1 | 2000 | 13 | 0.050 |
Why?
|
Risk | 1 | 2003 | 673 | 0.050 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2000 | 188 | 0.050 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2003 | 684 | 0.050 |
Why?
|
Immunity, Cellular | 1 | 2001 | 176 | 0.050 |
Why?
|
Risk Assessment | 2 | 2005 | 2252 | 0.050 |
Why?
|
Tumor Cells, Cultured | 5 | 2002 | 1040 | 0.050 |
Why?
|
Gene Expression | 2 | 2015 | 1279 | 0.050 |
Why?
|
Cisplatin | 1 | 2002 | 604 | 0.050 |
Why?
|
Databases as Topic | 1 | 2000 | 92 | 0.050 |
Why?
|
Mice, Nude | 5 | 2002 | 790 | 0.050 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2005 | 927 | 0.040 |
Why?
|
Cancer Vaccines | 1 | 2001 | 156 | 0.040 |
Why?
|
Carcinoma, Lobular | 1 | 2000 | 80 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2005 | 1376 | 0.040 |
Why?
|
Plasminogen | 1 | 1998 | 41 | 0.040 |
Why?
|
Apoptosis | 3 | 2008 | 1678 | 0.040 |
Why?
|
Genetic Vectors | 4 | 2004 | 438 | 0.040 |
Why?
|
Class II Phosphatidylinositol 3-Kinases | 1 | 2018 | 8 | 0.040 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2000 | 156 | 0.040 |
Why?
|
Research | 2 | 2003 | 252 | 0.040 |
Why?
|
Receptor, Notch1 | 1 | 2018 | 84 | 0.040 |
Why?
|
Transcription, Genetic | 1 | 2002 | 1127 | 0.040 |
Why?
|
Paraffin Embedding | 1 | 1997 | 78 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2003 | 1794 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2011 | 458 | 0.040 |
Why?
|
Mutagenesis | 1 | 1997 | 199 | 0.040 |
Why?
|
Adrenalectomy | 1 | 1996 | 43 | 0.040 |
Why?
|
Axilla | 1 | 1997 | 97 | 0.040 |
Why?
|
Neoplasm Proteins | 1 | 2000 | 532 | 0.040 |
Why?
|
Insurance, Health | 1 | 1998 | 158 | 0.040 |
Why?
|
Ovariectomy | 1 | 1996 | 81 | 0.040 |
Why?
|
Peptide Fragments | 1 | 1998 | 459 | 0.040 |
Why?
|
HCT116 Cells | 1 | 2016 | 150 | 0.040 |
Why?
|
Researcher-Subject Relations | 1 | 1996 | 4 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2018 | 407 | 0.040 |
Why?
|
Molecular Biology | 1 | 1996 | 89 | 0.030 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 1073 | 0.030 |
Why?
|
Immunotherapy | 1 | 2001 | 626 | 0.030 |
Why?
|
Social Responsibility | 1 | 1996 | 57 | 0.030 |
Why?
|
Fibrosarcoma | 1 | 1995 | 84 | 0.030 |
Why?
|
Luminescent Measurements | 1 | 2015 | 57 | 0.030 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 1996 | 176 | 0.030 |
Why?
|
Cell Nucleus | 1 | 1997 | 578 | 0.030 |
Why?
|
DNA Repair | 1 | 1997 | 356 | 0.030 |
Why?
|
Laryngeal Neoplasms | 1 | 1995 | 89 | 0.030 |
Why?
|
Algorithms | 1 | 2003 | 1827 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2015 | 187 | 0.030 |
Why?
|
Likelihood Functions | 1 | 1995 | 251 | 0.030 |
Why?
|
Mice, SCID | 1 | 2015 | 252 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 1996 | 857 | 0.030 |
Why?
|
Research Design | 2 | 2003 | 593 | 0.030 |
Why?
|
Tumor Burden | 1 | 2015 | 288 | 0.030 |
Why?
|
Neoplasms, Experimental | 1 | 1995 | 269 | 0.030 |
Why?
|
Social Values | 1 | 1994 | 44 | 0.030 |
Why?
|
Socioeconomic Factors | 1 | 1996 | 567 | 0.030 |
Why?
|
Regression Analysis | 1 | 1995 | 595 | 0.030 |
Why?
|
Diffusion of Innovation | 1 | 1994 | 71 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 1995 | 381 | 0.030 |
Why?
|
Genetic Diseases, Inborn | 1 | 1994 | 101 | 0.030 |
Why?
|
Health Care Costs | 1 | 1995 | 237 | 0.030 |
Why?
|
Patient-Centered Care | 1 | 1995 | 202 | 0.030 |
Why?
|
Forecasting | 1 | 1994 | 303 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 1 | 2016 | 579 | 0.030 |
Why?
|
Molecular Targeted Therapy | 1 | 2014 | 266 | 0.030 |
Why?
|
Adenoviridae | 2 | 2004 | 345 | 0.030 |
Why?
|
Social Change | 1 | 1991 | 7 | 0.030 |
Why?
|
England | 1 | 1991 | 41 | 0.030 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1991 | 78 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2011 | 270 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2011 | 369 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 1991 | 153 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2011 | 259 | 0.020 |
Why?
|
Precision Medicine | 1 | 2014 | 393 | 0.020 |
Why?
|
Promoter Regions, Genetic | 2 | 2004 | 933 | 0.020 |
Why?
|
Carcinoma, Squamous Cell | 1 | 1996 | 1075 | 0.020 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2008 | 20 | 0.020 |
Why?
|
Etanercept | 1 | 2008 | 32 | 0.020 |
Why?
|
Esophageal Neoplasms | 2 | 2002 | 320 | 0.020 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2008 | 43 | 0.020 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2008 | 87 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 1993 | 508 | 0.020 |
Why?
|
Rats | 2 | 2004 | 3982 | 0.020 |
Why?
|
Double-Blind Method | 1 | 1991 | 1816 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2008 | 455 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 1991 | 421 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2011 | 1196 | 0.020 |
Why?
|
Retrospective Studies | 1 | 2000 | 8406 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2008 | 424 | 0.020 |
Why?
|
Necrosis | 2 | 1996 | 204 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2011 | 2698 | 0.020 |
Why?
|
Pleural Effusion | 1 | 2004 | 45 | 0.020 |
Why?
|
Organoplatinum Compounds | 1 | 2004 | 94 | 0.020 |
Why?
|
Acetylcysteine | 1 | 2004 | 69 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 2 | 1996 | 555 | 0.020 |
Why?
|
Biopsy, Needle | 1 | 2004 | 234 | 0.010 |
Why?
|
Genes, erbB-2 | 1 | 2003 | 24 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2008 | 977 | 0.010 |
Why?
|
Probability | 1 | 2004 | 355 | 0.010 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2003 | 33 | 0.010 |
Why?
|
Mice, Inbred C57BL | 2 | 2000 | 3077 | 0.010 |
Why?
|
Receptors, Steroid | 1 | 2003 | 42 | 0.010 |
Why?
|
Paclitaxel | 1 | 2004 | 460 | 0.010 |
Why?
|
DNA, Complementary | 1 | 2002 | 392 | 0.010 |
Why?
|
Phytotherapy | 1 | 2003 | 132 | 0.010 |
Why?
|
Up-Regulation | 1 | 2004 | 710 | 0.010 |
Why?
|
Isocoumarins | 1 | 2000 | 7 | 0.010 |
Why?
|
Umbilical Veins | 1 | 2000 | 46 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2004 | 589 | 0.010 |
Why?
|
Laminin | 1 | 2000 | 85 | 0.010 |
Why?
|
ROC Curve | 1 | 2003 | 752 | 0.010 |
Why?
|
Drug Combinations | 1 | 2000 | 222 | 0.010 |
Why?
|
Proteoglycans | 1 | 2000 | 121 | 0.010 |
Why?
|
Mass Screening | 1 | 2004 | 615 | 0.010 |
Why?
|
Collagen | 1 | 2000 | 268 | 0.010 |
Why?
|
Angiostatins | 1 | 1998 | 15 | 0.010 |
Why?
|
Cytokines | 1 | 2003 | 775 | 0.010 |
Why?
|
Endothelium, Vascular | 1 | 2000 | 435 | 0.010 |
Why?
|
Colonic Neoplasms | 1 | 2002 | 553 | 0.010 |
Why?
|
Cohort Studies | 1 | 2004 | 2759 | 0.010 |
Why?
|
Cell Movement | 1 | 2000 | 754 | 0.010 |
Why?
|
Biomarkers | 1 | 2003 | 1707 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2000 | 1958 | 0.010 |
Why?
|
Mastadenovirus | 1 | 1995 | 4 | 0.010 |
Why?
|
Liposomes | 1 | 1995 | 91 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2000 | 2802 | 0.010 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 1995 | 109 | 0.010 |
Why?
|
Radiation Tolerance | 1 | 1995 | 168 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 1995 | 363 | 0.010 |
Why?
|
Thrombosis | 1 | 1996 | 296 | 0.010 |
Why?
|
Signal Transduction | 1 | 2003 | 3226 | 0.010 |
Why?
|